The aberrant activation of the FGFR signaling is detected in many solid tumors, including pancreatic ductal adenocarcinoma (PDAC), suggesting it as a potential therapeutic target. In this study, we investigated the antitumor and anti-metastasis efficacy of the selective FGFR1 inhibitor, PD173074 in PDAC. We used immunohistochemical and in situ hybridization analyses to demonstrate a strong correlation between FGFR1 amplification and/or expression and disease progression in PDAC patients. We showed that ALDHhigh (ALDH+) pancreatic cancer cells exhibited stem cell-like phenotype and expressed higher levels of FGFR1, Src, NF-κB, alongside stemness markers like Oct4 and Sox2, compared to their ALDHlow/null (ALDH−) counterparts, suggesting the preferential activation of the FGFR1/Src/NF-κB signaling axis in pancreatic cancer stem cells (panCSCs). Furthermore, treatment of the ALDHhigh/ FGFR1-rich pancreatic cancer cell lines with PD173074, a selective FGFR1 inhibitor, revealed that PD173074 inhibited the proliferation and self-renewal of the panCSCs, and induced their apoptosis by activating caspase-3 and cleaving Poly-ADP ribose Polymerase (PARP). The anti-CSCs effect of PD173074 was associated with decreased expression of Oct4, Sox-2, Nanog, and c-Myc, as well as suppression of XIAP, Bcl2, and survivin expression, dose-dependently. Additionally, activation of cMet, Src, ERK 1/2 and NFκB (p65) was also inhibited by PD173074. Also, of clinical relevance, the disruption of the FGFR1/Src/NF-κB signaling axis positively correlated with poor clinical prognosis among the PDAC patients. We concluded that PD173074 suppresses the tumorigenesis and CSCs-like phenotype of PDAC cells, highlighting its therapeutic efficacy and providing support for its potential use as a therapeutic option for the ‘difficult-to-treat’, ‘quick-to-relapse’ PDAC patients.
Schematic abstract showing how PD173074 inhibits PDAC growth through selective targeting of FGFR1, suppression of cancer stemness, disruption of the FGFR1/Src/NF-κB signaling axis and activation of the cell death signaling pathway.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
The datasets used and analyzed in the current study are available from the corresponding author in response to reasonable requests.
Pancreatic ductal adenocarcinoma
Cancer stem cells
Pancreatic cancer stem cells
Fibroblast growth factor receptor 1
ATP-binding cassette transporters
Hematoxylin and eosin
Vascular endothelial growth factor
Fibroblast growth factor receptor
Platelet-derived growth factor receptors
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer. Available at http://globocan.iarc.fr. Accessed 11 July 2017
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (2011) Pancreatic cancer. Lancet 378(9791):607–620
Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA et al (2011) Stromal biology and therapy in pancreatic cancer. Gut 60(6):861–868
Li Y, Kong D, Ahmad A, Bao B, Sarkar FH (2013) Pancreatic cancer stem cells: emerging target for designing novel therapy. Cancer Lett 338(1):94–100
Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M et al (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1(3):313–323
Ding Q, Yoshimitsu M, Kuwahata T, Maeda K, Hayashi T, Obara T et al (2011) Establishment of a highly migratory subclone reveals that CD133 contributes to migration and invasion through epithelial–mesenchymal transition in pancreatic cancer. Hum Cell 25(1):1–8
Hong SP, Wen J, Bang S, Park S, Song SY (2009) CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 125(10):2323–2331
Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH et al (2011) c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 141(6):2218–2227 e5
Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S et al (2011) ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS ONE 6(6):e20636
Lehnen NC, von Massenhausen A, Kalthoff H, Zhou H, Glowka T, Schutte U et al (2013) Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. Histopathology 63:157–166
Ishiwata T, Matsuda Y, Yamamoto T, Uchida E, Korc M, Naito Z (2012) Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. Am J Pathol 180(5):1928–1941
Ornitz DM, Itoh N (2015) The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol 4(3):215–266
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28735. Accessed 3 June 2017
https://string-db.org/cgi/network.pl? Accessed 4 June 2017
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21501. Accessed 4 June 2017
Scientific Framework for Pancreatic Ductal Adenocarcinoma (PDAC). NAtional CAncer Institute (2014) https://deainfo.nci.nih.gov/advisory/ctac/ workgroup/pc/ pdacframework.pdf. Accessed 11 April 2017
Ellenrieder V, König A, Seufferlein T (2016) Current standard and future perspectives in first- and second-line treatment of metastatic pancreatic adenocarcinoma. Digestion 94(1):44–49
Yee NS (2016) Immunotherapeutic approaches in pancreatic adenocarcinoma: current status and future perspectives. Curr Mol Pharmacol 9(3):231–241
Adamska A, Domenichini A, Falasca M (2017) Pancreatic ductal adenocarcinoma: current and evolving therapies. Int J Mol Sci 18(7):E1338
Ji W, Yu Y, Li Z, Wang G, Li F, Xia W, Lu S (2016) FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway. Oncotarget 7(12):15118–15134
Anreddy N, Patel A, Sodani K, Kathawala RJ, Chen EP, Wurpel JN, Chen ZS (2014) PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR. Acta Pharm Sin B 4(3):202–207. https://doi.org/10.1016/j.apsb.2014.02.003
Jin Z, El-Deiry WS (2005) Overview of cell death signaling pathways. Cancer Biol Ther 4(2):139–163
Oberoi-Khanuja TK, Murali A, Rajalingam K (2013) IAPs on the move: role of inhibitors of apoptosis proteins in cell migration. Cell Death Dis 4(9):e784. https://doi.org/10.1038/cddis.2013.311
Gyrd-Hansen M, Meier P (2010) IAPs: aaafrom caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 10(8):561–574
Lee HS, Moon C, Lee HW, Park EM, Cho MS, Kang JL (2007) Src tyrosine kinases mediate activations of NF-kappaB and integrin signal during lipopolysaccharide-induced acute lung injury. J Immunol 179(10):7001–7011
Auciello G, Cunningham DL, Tatar T, Heath JK, Rappoport JZ (2013) Receptor of fibroblast growth receptor signaling and trafficking by Src and Eps8. J Cell Sci 126(2):613–624
This work was supported by National Science Council of Taiwan: Tsu-Yi Chao (MOST103-2325-B-038-002 and MOST105-2314-B038-080), and Wei-Hwa Lee (MOST 105-2320-B-038-054). This study was also supported by Grants from Taipei Medical University (105TMU-SHH-15) to Wei-Hwa Lee and grants from Taipei Medical University -National Taiwan University of Science and Technology Joint Research Program (TMU-NTUST-103-03) to Chi-Tai Yeh. Grants from Tri-Service General Hospital Penghu Branch, Penghu, Taiwan (TSGH-PH-105-3, TSGH-PH-106-4) to Shiue-Wei Lai.
Conflict of interest
All authors are working for either university or hospitals. We claim that we do not have any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the work submitted that could inappropriately influence our work.
This study was conducted in a cohort of patients with pancreatic cancer who underwent pancreaticoduodenectomy at Tri-Service General Hospital, Taipei, Taiwan between January 2000 and December 2013. A predesigned data collection format was used to review the patients’ medical records for evaluation of clinicopathologic characteristics and survival outcomes. The study was reviewed and approved by the institute review board (TSGHIRB 2-104-05-040).
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Lai, S., Bamodu, O.A., Tsai, W. et al. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity. Clin Exp Metastasis 35, 663–677 (2018). https://doi.org/10.1007/s10585-018-9919-5
- Pancreatic cancer
- Selective inhibitor
- Cancer stem cells
- FGFR1/Src/NF-κB signaling